Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells
- PMID: 16173028
- DOI: 10.1002/pros.20340
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells
Abstract
Background: TGF-beta is a potent immunosuppressant. High levels of TGF-beta produced by cancer cells have a negative inhibition effect on surrounding host immune cells and leads to evasion of the host immune surveillance and tumor progression. In the present study, we report a distinct ability of tumor reactive, TGF-beta-insensitive CD8+ T cells to infiltrate into established tumors, secrete relevant cytokines, and induce apoptosis of tumor cells.
Methods: CD8+ T cells were isolated from the spleens of C57BL/6 mice, which were primed with irradiated mouse prostate cancer cells, the TRAMP-C2 cells. After ex vivo expansion, these tumor reactive CD8+ cells were rendered TGF-beta-insensitive by infection with a retroviral (MSCV)-mediated dominant negative TGF-beta type II receptor (TbetaRIIDN). Control CD8+ cells consist of those transfected with the GFP-only empty vector and naïve CD8+ T cells. Recipient mice were challenged with a single injection of TRAMP-C2 cells 21 days before adoptive transfer of CD8+ T cells was performed. Forty days after the adoptive transfer, all animals were sacrificed. The presence of pulmonary metastases was evaluated pathologically. Serial slides of malignant tissues were used for immunofluorescent staining for different kinds of immune cell infiltration, cytokines, and apoptosis analysis.
Results: Pulmonary metastases were either eliminated or significantly reduced in the group receiving adoptive transfer of tumor-reactive TGF-beta-insensitive CD8+ T cells (3 out of 12) when compared to GFP controls (9 out of 12), and naïve CD8+ T cells (12 out of 12). Results of immunofluorescent studies demonstrated that only tumor-reactive TGF-beta-insensitive CD8+ T cells were able to infiltrate into the tumor and mediate apoptosis when compared to CD4+ T cells, NK cells, and B cells. A large amount of cytokines such as perforin, nitric oxide, IFN-gamma, IL-2, TNF-alpha were secreted in tumor tissue treated with tumor-reactive TGF-beta-insensitive CD8+ T cells. No immune cells infiltration and cytokine secretion were detected in tumor tissues treated with naïve T cells and GFP controls.
Conclusions: Our results demonstrate the mechanism of anti-tumor effect of tumor-reactive TGF-beta-insensitive CD8+ T cells that adoptive transfer of these CD8+ T cells resulted in infiltration of these immune cells into the tumor parenchyma, secretion of relevant cytokines, and induction of apoptosis in tumor cells. These results support the concept that tumor-reactive TGF-beta-insensitive CD8+ T cells may prove beneficial in the treatment of advanced cancer patients.
Copyright (c) 2005 Wiley-Liss, Inc.
Similar articles
-
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.Cancer Res. 2005 Mar 1;65(5):1761-9. doi: 10.1158/0008-5472.CAN-04-3169. Cancer Res. 2005. PMID: 15753372
-
Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.Clin Cancer Res. 2010 Jan 1;16(1):164-73. doi: 10.1158/1078-0432.CCR-09-1758. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028741
-
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors.Urology. 2008 Oct;72(4):943-7. doi: 10.1016/j.urology.2008.04.017. Epub 2008 Aug 23. Urology. 2008. PMID: 18723212
-
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21. Eur Urol. 2018. PMID: 29275833 Free PMC article. Review.
-
The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.Cancer. 2004 Jun 1;100(11):2281-91. doi: 10.1002/cncr.20270. Cancer. 2004. PMID: 15160330 Review.
Cited by
-
TGF-β: duality of function between tumor prevention and carcinogenesis.J Natl Cancer Inst. 2014 Feb;106(2):djt369. doi: 10.1093/jnci/djt369. J Natl Cancer Inst. 2014. PMID: 24511106 Free PMC article. Review.
-
TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.Cancer Immunol Immunother. 2007 Nov;56(11):1785-93. doi: 10.1007/s00262-007-0322-3. Epub 2007 May 1. Cancer Immunol Immunother. 2007. PMID: 17473921 Free PMC article.
-
The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function.Sci Signal. 2016 Mar 8;9(418):ra27. doi: 10.1126/scisignal.aad1242. Sci Signal. 2016. PMID: 26956486 Free PMC article.
-
Mechanisms navigating the TGF-β pathway in prostate cancer.Asian J Urol. 2015 Jan;2(1):11-18. doi: 10.1016/j.ajur.2015.04.011. Epub 2015 Apr 16. Asian J Urol. 2015. PMID: 29051866 Free PMC article.
-
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity.J Clin Med. 2016 Aug 31;5(9):76. doi: 10.3390/jcm5090076. J Clin Med. 2016. PMID: 27589814 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous